ReviewJournal of clinical laboratory analysis2022
Roles of biomarkers in anti-MDA5-positive dermatomyositis, associated interstitial lung disease, and rapidly progressive interstitial lung disease.
Review in Journal of clinical laboratory analysis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 28 citations in OpenAlex.
- Plasma exchange in adult idiopathic inflammatory myositis: a systematic review and meta-analysis.Clinical rheumatology · 2026Pooled it
- The efficacy and safety of tofacitinib in anti-melanoma differentiation-associated gene 5 antibody positive dermatomyositis associated interstitial lung disease: a systematic review and meta-analysis.Therapeutic advances in respiratory diseasePooled it
- Systemic Autoimmune Rheumatic Disease-Associated Interstitial Lung Disease: A Pulmonary Perspective on Recent Guidelines.Advances in therapy · 2026Review
- High-resolution computed tomography assessment of connective tissue disease-associated interstitial lung disease: Advances in diagnosis and prognostic evaluation.World journal of radiology · 2026Review
- Clinical characteristics and prognostic markers of anti-MDA5 antibody-positive dermatomyositis-associated interstitial lung disease: a retrospective cohort study.Journal of thoracic disease · 2026Article
- Update on clinimetric assessments in juvenile dermatomyositis: conceptual foundations, current tools, and future directions : (Narrative review describing the development, validation, and application of clinimetric outcome measures in juvenile dermatomyositis).Pediatric rheumatology online journal · 2026Review
- Towards New Strategies: Case Report and Review of the Literature-Effective Use of JAK Inhibitor Baricitinib in a 4-Year-Old Boy with Anti-MDA5 Antibody-Positive Juvenile Dermatomyositis.Journal of clinical medicine · 2026Article
- Clinical features and prognostic factors of anti-MDA5 antibody-positive dermatomyositis-associated interstitial lung disease with spontaneous mediastinal emphysema: a retrospective case series of nine patients.Frontiers in medicine · 2026Article
- Gradient elevation of serum CYFRA21-1 and its synergy with KL-6 for risk stratification in rheumatoid arthritis-associated interstitial lung disease.Frontiers in medicine · 2026Article
- Anti-MDA5 antibody IgG1 subtype is associated with rapidly progressive interstitial lung disease in anti-MDA5-positive dermatomyositis.Orphanet journal of rare diseases · 2025Article
- Dynamics of serum tumor markers may indicate the progression of interstitial lung disease in Sjögren's syndrome patients: new roles for old friends.Clinical and experimental medicine · 2025Article
- Clinical characteristics and prognosis of amyopathic dermatomyositis patients with interstitial lung disease: insights from a retrospective cohort.Orphanet journal of rare diseases · 2025Article
- Two fatal cases of anti-melanoma differentiation-associated gene 5 antibody (anti-MDA5) rapidly progressive interstitial lung disease (RP-ILD): Exploring pitfalls and differences.Respiratory medicine case reports · 2025Article
- Dynamic change of lymphocytes associated with short-term prognosis in anti-MDA5-positive dermatomyositis with interstitial lung disease: a multicenter retrospective study.Clinical rheumatology · 2024Article
- Multivariate logistic regression analysis of poor prognosis of dermatomyositis and clinical value of ferritin/Kl-6 in predicting prognosis.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2024Article
- Targeting Progression in Pulmonary Fibrosis: An Overview of Underlying Mechanisms, Molecular Biomarkers, and Therapeutic Intervention.Life (Basel, Switzerland) · 2024Review
- Pathogenic mechanisms of disease in idiopathic inflammatory myopathies: autoantibodies as clues.Frontiers in immunology · 2024Review
- Efficacy and safety of dose escalation of tofacitinib in refractory anti-MDA5 antibody-positive dermatomyositis.RMD open · 2023Article
- Roles of biomarkers in anti-MDA5-positive dermatomyositis, associated interstitial lung disease, and rapidly progressive interstitial lung disease.Journal of clinical laboratory analysis · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
backgroundAnti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis (MDA5
methodsRecent relative studies related to blood biomarkers in PubMed were reviewed.
resultsAn increasing number of studies have demonstrated that dysregulated expression of blood biomarkers related to ILD such as ferritin, Krebs von den Lungen-6 (KL-6), surfactant protein-D (SP-D), and cytokines, and some tumor markers in MDA5
conclusionsTherefore, this review may provide insight to guide treatment decisions for MDA5
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.